¼¼°èÀÇ ºñÈ£¸£¸ó¼º ÇÇÀÓ¾à ½ÃÀå : ±âȸ, ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Non-Hormonal Contraceptives Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1755217
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,640,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,283,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,431,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ºñÈ£¸£¸ó¼º ÇÇÀÓ¾à ½ÃÀåÀº 2024³â 199¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç 2034³â¿¡´Â 391¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 7%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¾ÈÀüÇÑ ¼ºÇàÀ§¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í, Á¤ºÎÀÇ Áö¿ø Á¤Ã¥°ú È£¸£¸óÀÌ ÇÔÀ¯µÇÁö ¾ÊÀº ÇÇÀÓ¾àÀ¸·ÎÀÇ ÀüȯÀÌ µÎµå·¯Áö°Ô ÁøÇàµÇ¸é¼­ ½ÃÀå È®ÀåÀÌ °è¼Ó ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. È£¸£¸ó ¹æ¹ý°ú ¿¬°üµÈ ºÎÀÛ¿ëÀ» ÇÇÇÏ·Á´Â ¼ÒºñÀÚµéÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, È£¸£¸óÀ» »ç¿ëÇÏÁö ¾Ê´Â ÇÇÀÓ ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºñÈ£¸£¸ó ÇÇÀÓ¾à ½ÃÀå-IMG1

Äܵ¼°ú °°Àº Á¢±Ù¼ºÀÌ ³ô°í »ç¿ëÀÌ Æí¸®ÇÑ ÇÇÀÓ ¼ö´Ü¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå µ¿Çâ¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °³¹ßµµ»ó Áö¿ª¿¡¼­ ³²¼ºµé »çÀÌ¿¡¼­ ½ÃÀå Á¡À¯À²ÀÌ ³ô°Ô ³ªÅ¸³­ °ÍÀº °¡°Ý ºÎ´ãÀÌ Àû°í, Á¢±Ù¼ºÀÌ ¿ì¼öÇϸç, ÀӽŰú ¼ºº´(STD)¿¡ ´ëÇÑ ÀÌÁß º¸È£ È¿°ú¸¦ Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. ¸¹Àº »ç¿ëÀÚµéÀÌ ±âºÐ º¯È­, üÁß Áõ°¡¿Í °°Àº ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ È£¸£¸ó ±â¹ÝÀÇ ÇÇÀÓ¹ýÀ» ¸Ö¸®Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ´õ ¾ÈÀüÇÑ ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ ¼Ò¸Å ¹× µðÁöÅРä³ÎÀ» ÅëÇØ Á¦Ç°À» Æø³Ð°Ô °ø±ÞÇÔÀ¸·Î½á ¼ÒºñÀÚÀÇ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. Á¦Ç°Àº ¿Â¶óÀÎ Ç÷§Æû, ¾à±¹ üÀÎ, Àα٠¼Ò¸ÅÁ¡À» ÅëÇØ Æí¸®ÇÏ°Ô ±¸¸ÅÇÒ ¼ö ÀÖ¾î Áö¼ÓÀûÀÎ »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ Á¾ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ÇâÈÄ ¸î ³â µ¿¾È ¼ºÀåÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 199¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 391¾ï ´Þ·¯
CAGR 7%

µð¹ÙÀ̽º ºÎ¹®Àº 2034³â±îÁö ¿¬Æò±Õ 7.2%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 294¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ÁÖ¿ä Á¦Ç°À¸·Î´Â Àڱà ³» ÀåÄ¡(IUD), ÇÇÇÏ ÀÓÇöõÆ®, Áú¸µ, Äܵ¼ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ Áß ±¸¸® IUD´Â È¿°ú¿Í È£¸£¸óÀÌ ÇÔÀ¯µÇ¾î ÀÖÁö ¾Ê´Ù´Â Ư¼ºÀ¸·Î ÀÎÇØ ³Î¸® ¼±È£µÇ°í ÀÖ½À´Ï´Ù. Äܵ¼Àº Á¢±Ù¼ºÀÌ ¶Ù¾î³ª°í °¨¿°¿¡ ´ëÇÑ Ãß°¡ÀûÀÎ º¸È£ ±â´ÉÀ» Á¦°øÇϱ⠶§¹®¿¡ ÇʼöÀûÀÎ ÇÇÀÓ ¹æ¹ýÀ¸·Î ³²¾Æ ÀÖÀ¸¸ç, ºñÈ£¸£¸ó ÇÇÀÓ¾à ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

2024³â¿¡´Â ¿©¼º »ç¿ëÀÚ ºÎ¹®ÀÌ 126¾ï ´Þ·¯¸¦ Â÷ÁöÇß½À´Ï´Ù. ¿©¼ºµéÀº Àå±â°£ À¯È¿ÇÑ °¡¿ªÀû ÇÇÀÓ¾à(LARCs), »ìÁ¤Á¦, ÀÓÇöõÆ®, ³­°ü °áÂû¼ú°ú °°Àº ¼ö¼úÀû ½Ã¼ú µî ºñÈ£¸£¸ó¼º ÇÇÀÓ¹ýÀ» °è¼Ó ¼±ÅÃÇϰí ÀÖ½À´Ï´Ù. ¼±ÅÃÀº ÆíÀǼº, °Ç°­ ¿äÀÎ, Àå±âÀûÀÎ ½Å·Ú¼º µî¿¡ ÀÇÇØ Á¿ìµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ³­°ü °áÂû¼úÀº ³­°üÀ» ¸·¾Æ ¿µ±¸ÀûÀÎ ºÒÀÓ È¿°ú¸¦ Á¦°øÇÏ´Â ¼ö¼ú·Î, Æó°æÀ» ¾ÕµÐ 40¼¼ ÀÌ»ó ¿©¼ºµéÀÌ ½Å·ÚÇÒ ¼ö ÀÖ´Â ÇÇÀÓ ¹æ¹ýÀ» ãÀ¸¸é¼­ ³Î¸® ¼±Åõǰí ÀÖ½À´Ï´Ù. °¡Ã³ºÐ ¼Òµæ Áõ°¡, ¿©¼ºÀÇ ³ëµ¿·Â Âü¿© È®´ë, »ý½Ä °Ç°­ ÀÎ½Ä Çâ»óµµ äÅ÷ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ ºñÈ£¸£¸ó¼º ÇÇÀÓ¾à 2024³â ½ÃÀå ±Ô¸ð´Â 58¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. ´Ù³¶¼º ³­¼Ò ÁõÈıºÀ̳ª °©»ó¼± Àå¾Ö¿Í °°Àº È£¸£¸ó ÁúȯÀ» °ü¸®ÇÏ´Â °³ÀÎÀº ºñÈ£¸£¸ó ¿É¼ÇÀ» ÀÚÁÖ ¼±ÅÃÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀº ³«Å¿¡ ´ëÇÑ ¹®È­Àû ¹× ¹ýÀû Á¦ÇÑÀÇ Â÷ÀÌ·Î ÀÎÇØ ÇÇÀÓ »ç¿ëÀÌ Áõ°¡ÇÏ´Â µ¥ Ãß°¡·Î Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ³²³à ¸ðµÎ¸¦ À§ÇÑ ÃÖ¼Ò Ä§½ÀÀû ¿É¼ÇÀ» Æ÷ÇÔÇÑ ºÒÀÓ ±â¼úÀÇ ¹ßÀüÀº ȯÀÚ °æÇè°ú ¼ö¿ëµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾÷°è Ç÷¹À̾îµéÀº ³²¼º ÇÇÀÓ¿ë Â÷¼¼´ë ¼Ö·ç¼Ç °³¹ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ÁÖ»çÇü ¼öÈ­°Ö ±â¹Ý ¹æ¹ýÀÌ ¹Ì·¡ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ºñÈ£¸£¸ó¼º ÇÇÀÓ¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Bayer, Reckitt, Mayer, HLL Lifecare, PREGNA INTERNATIONAL, FUJI LATEX, Mankind, CooperCompanies, Church & Dwight Co., SMB, CUPID, Okamoto, abbVie, VIATRIS µîÀÔ´Ï´Ù. ºñÈ£¸£¸ó ÇÇÀÓÁ¦ ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ÁÖ¿ä ±â¾÷µéÀº Á¦Ç° µðÀÚÀÎ Çõ½ÅÀ» ¿ì¼±¼øÀ§·Î »ï°í, À¯Åë ä³ÎÀ» È®ÀåÇϸç, Ÿ°ÙÆÃµÈ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀº »ç¿ëÀÚÀÇ ÆíÀǼº, È¿À²¼º, Á¢±Ù¼ºÀ» ³ôÀÌ´Â °í±Þ À庮 ÀåÄ¡¿Í ºÒÀÓ µµ±¸ °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ¹®È­Àû ±Ý±â¸¦ ±ú°í Á¤º¸¿¡ ±â¹ÝÇÑ ¼±ÅÃÀ» Àå·ÁÇϱâ À§ÇØ »ç¿ëÀÚ Áß½ÉÀÇ ±³À°¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ °íÂû

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : À¯Çüº°(2021-2034³â)

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ¼ºº°(2021-2034³â)

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ¿¬·ÉÃþº°(2021-2034³â)

Á¦8Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Non-Hormonal Contraceptives Market was valued at USD 19.9 billion in 2024 and is estimated to grow at a CAGR of 7% to reach USD 39.1 billion by 2034. Rising public awareness around safe sexual practices, combined with supportive government initiatives and a noticeable shift toward hormone-free contraceptive solutions, continues to drive market expansion. A growing number of consumers are seeking birth control options that avoid the side effects commonly linked with hormonal methods.

Non-Hormonal Contraceptives Market - IMG1

An increasing preference for accessible and easy-to-use contraceptives like condoms has positively impacted market dynamics. The market had a strong uptake among men in developing regions due to affordability, availability, and dual protection against pregnancy and STDs. Many users are moving away from hormone-based options due to side effects such as mood fluctuations and weight gain, contributing to the growing demand for safer alternatives. Additionally, wide product availability through multiple retail and digital channels enhances consumer access. Products are conveniently offered via online platforms, drugstore chains, and nearby retail outlets, encouraging consistent adoption. These factors are collectively expected to sustain growth in the coming years.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$19.9 Billion
Forecast Value$39.1 Billion
CAGR7%

The devices segment is projected to achieve a CAGR of 7.2%, reaching USD 29.4 billion by 2034. Key products in this segment include intrauterine devices (IUDs), subdermal implants, vaginal rings, and condoms. Among these, copper IUDs have become widely preferred due to their effectiveness and hormone-free nature. Condoms remain an essential method due to their accessibility and added protection against infections, making them a dominant player in the non-hormonal contraceptives space.

In 2024, the female user segment accounted for USD 12.6 billion. Women continue to opt for non-hormonal solutions including long-acting reversible contraceptives (LARCs), spermicidal products, implants, and surgical procedures like tubectomy. Choices are often influenced by convenience, health factors, and long-term reliability. Tubal ligation, a permanent sterilization procedure involving the closure of fallopian tubes, is commonly selected by women over 40 who seek a dependable birth control method as they approach menopause. Rising disposable income, increased participation of women in the workforce, and greater reproductive health awareness are also contributing to higher adoption.

U.S. Non-Hormonal Contraceptives Market was valued at USD 5.8 billion in 2024. Individuals managing hormonal conditions such as polycystic ovary syndrome or thyroid disorders often rely on non-hormonal options. Market growth is further supported by varying cultural and legal restrictions on abortion, prompting greater use of contraception. Technological advances in sterilization, including minimally invasive options for both men and women, are improving patient experience and acceptance. Additionally, industry players are focusing on developing next-generation solutions for male contraception, including injectable hydrogel-based methods, which is expected to boost future demand.

Key companies in the Global Non-Hormonal Contraceptives Market include: Bayer, Reckitt, MAYER, HLL Lifecare, PREGNA INTERNATIONAL, FUJI LATEX, Mankind, CooperCompanies, Church & Dwight Co., SMB, CUPID, Okamoto, abbVie, and VIATRIS. To strengthen their foothold in the non-hormonal contraceptives sector, leading companies prioritize innovation in product design, expand distribution channels, and launch targeted awareness campaigns. Many are developing advanced barrier devices and sterilization tools that offer greater comfort, efficiency, and accessibility. Companies invest in user-centric education to break cultural taboos and promote informed choices.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â